This article was originally published in The Tan Sheet
Teva Pharmaceuticals' acquisition of fellow generics firm Ivax is expected to close on Jan. 12, 2006, the firms state in a joint release Dec. 23. The Israeli firm Teva and the Miami, Fla.-based Ivax have now signed a consent order for submission to FTC, which is "the last remaining regulatory condition to the consummation of the transaction," the release states. The deal cannot close until FTC approves a consent order, they note. The planned acquisition was announced in July 2005 ("The Tan Sheet" Aug. 1, 2005, p. 11)...
You may also be interested in...
Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.